Marketing: Page 2
-
Lilly reveals Humalog pricing details amid larger scrutiny over insulin costs
The average list price on the widely used insulin rose more than 50% from 2014 to 2018, though Lilly noted the drug's average net price declined 8%.
By Jacob Bell • March 25, 2019 -
Specialty drug costs skyrocketed to $33B in Medicare Part D in 2015
Brand-name specialty drugs accounted for only 1% of all prescriptions in both Medicare Part D and Medicaid, but accounted for 30% of net spending.
By Rebecca Pifer • March 21, 2019 -
Sage's postpartum depression drug is approved. Now comes the hard part
Zulresso's label requires women to undergo a 60-hour infusion and only in certain settings, factors that may hamper the drug commercially.
By Jacob Bell • UPDATED: March 20, 2019 at 9:12 a.m. -
Gilead raises prices on top-selling HIV treatments
The biotech hiked prices on more than a dozen products, including six HIV medicines that each surpassed $1 billion in 2018 sales.
By Andrew Dunn • March 19, 2019 -
SponsoredGearing up for growth
Launch decisions have a lasting impact. Here’s how short-term focus leads to long term success.
-
Aerie's eye drops win FDA approval
Branded as Rocklatan, the drops share an active ingredient with another intraocular pressure drug called Rhopressa that Aerie launched last year.
By Kristin Jensen • March 13, 2019 -
Dupixent label expansion opens door to thousands more patients
A new approval in younger atopic dermatitis patients could increase the list of people eligible to use the immunology drug by 200,000, according to Sanofi.
By Jacob Bell • March 12, 2019 -
Pharmas, PBMs and payers all take a slice along drug supply chain, Pew finds
As debate over drug pricing continues, Pew's report seeks to document the share each player pockets as medicines move through the system.
By Les Masterson • March 11, 2019 -
Mylan's Advair generic pressures GSK with strong launch
Priced at a 70% discount, Mylan's copy of the blockbuster respiratory drug has quickly captured market share.
By Ned Pagliarulo • March 08, 2019 -
AMAG pregnancy drug's future in doubt after key study miss
A confirmatory trial designed to support Makena's approval failed, likely crimping its commercial prospects. Yet the drug may still remain on market.
By Jacob Bell • March 08, 2019 -
Lilly follows Gilead, Mylan lead with authorized generic play
A strategy to "cannibalize your own products before your competition does" — as one consultant put it — serves several purposes for drugmakers under pressure on price.
By Andrew Dunn • March 05, 2019 -
Lilly to launch generic of its insulin Humalog, cutting list price in half
Introduction of an authorized generic, though, may not dispel criticism of Lilly's pricing, which has come under scrutiny in recent years.
By Ned Pagliarulo , Andrew Dunn • March 04, 2019 -
AbbVie, Akcea benefit from latest CHMP recommendations
Risankizumab and volanesorsen, which would be marketed as Skyrizi and Waylivra, were among eight drugs that got committee support.
By Jacob Bell • March 01, 2019 -
Roche wins US approval of more convenient Herceptin
Treatment with subcutaneous Herceptin takes just a few minutes, rather than the sometimes hour and a half needed to administer the breast cancer drug intravenously.
By Ned Pagliarulo • March 01, 2019 -
So far, so good for Alexion's Soliris follow-on
Alexion is working to convert PNH patients to its newer Ultomiris, preparing for a future with biosimilar competition.
By Jacob Bell • Feb. 28, 2019 -
At Senate hearing, pharma shows split on biosimilars
Merck & Co. and Pfizer are eager to see biosimilar uptake encouraged, a position fellow big pharma J&J doesn't appear to share.
By Ned Pagliarulo • Feb. 27, 2019 -
Early Epidiolex sales push up GW Pharma's stock
The cannabis-based epilepsy therapy got off to a strong commercial start in the U.S., analysts said, although the drug's roll-out is still in early days.
By Andrew Dunn • Feb. 27, 2019 -
How lawmakers could pressure top pharma execs in Senate hearing
Here's a guide to the political pressure points for each of the seven drug companies in front of the Senate Finance Committee today.
By Ned Pagliarulo • Feb. 25, 2019 -
Intercept stock drop reflects the high bar set for NASH drugs
Though Intercept's drug Ocaliva did score the first Phase 3 victory against the fatty liver disease, investors still appear skeptical of the drug's prospects.
By Jacob Bell • Feb. 22, 2019 -
Dr. Reddy's relaunches Suboxone generic after court victories
A legal battle had stalled entry of Dr. Reddy's copy, which will now challenge Indivior's opioid dependence treatment in the U.S.
By Kristin Jensen • UPDATED: Feb. 22, 2019 at 9:36 a.m. -
Sanofi handed payers nearly $12B in drug rebates last year
That's why, despite increasing the U.S. list price on 35 of its 76 prescription drugs, the French pharma reported an average net price decline of 8% in 2018.
By Ned Pagliarulo • Feb. 21, 2019 -
US healthcare spending growth to hit 5.5% by 2027, CMS predicts
The ballooning American healthcare bill will outstrip GDP growth over the next decade, according to an annual government report.
By Rebecca Pifer • Feb. 20, 2019 -
CMS unveils CAR-T proposal, with emphasis on patient outcomes
High price tags and a potential one-time administration have challenged CMS to figure out reimbursement for CAR-T cell therapies.
By Jacob Bell • Feb. 15, 2019 -
Payers divided over best value-based payment model, survey finds
A new HealthEdge survey of 151 health insurance execs highlighted ongoing challenges to adoption, although utilization appears common.
By Les Masterson • Feb. 14, 2019 -
Mylan launches Advair generic at 70% discount
While a long time coming, Mylan's copycat version now looks set to take a bite out of GSK's respiratory drug sales.
By Suzanne Elvidge • Feb. 13, 2019
Previous
